Related Experiment Videos
Management of nephrotic syndrome in children
Renee F Robinson1, Milap C Nahata, John D Mahan
1Department of Pediatrics, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio, USA. Robinsonr@pediatrics.ohio-state.edu
Insights
Idiopathic childhood nephrotic syndrome treatment aims for remission with minimal toxicity. Current evidence supports various therapies, but further research is needed for optimal, least toxic regimens.
Area of Science:
- Pediatric Nephrology
- Pharmacology
- Clinical Evidence Assessment
Background:
- Idiopathic childhood nephrotic syndrome typically has a good long-term outlook.
- Advances in therapy administration and monitoring have reduced associated morbidity and mortality.
- The primary treatment objective is achieving rapid remission while mitigating complications and adverse events.
Purpose of the Study:
- To critically evaluate the clinical evidence supporting current pharmacologic therapies for childhood nephrotic syndrome.
- To discuss the risks and necessary monitoring parameters for optimizing each drug regimen.
- To identify the most effective and least toxic therapeutic strategies for remission induction and maintenance.
Main Methods:
- Systematic review and critical assessment of existing clinical evidence for pharmacologic treatments.
- Analysis of common corticosteroid therapies, cytotoxic agents (chlorambucil, cyclophosphamide), cyclosporine, levamisole, and experimental treatments.
- Evaluation of risks, monitoring requirements, and toxicity profiles for each therapeutic approach.
Main Results:
- Prompt remission is achievable with aggressive therapy, reducing relapse frequency in most cases.
- However, aggressive treatment regimens can lead to significant and unnecessary toxicity.
- Current evidence supports multiple therapeutic options, each with distinct risk-benefit profiles.
Conclusions:
- Further research is essential to pinpoint the most effective and least toxic treatment regimens for inducing and maintaining remission in pediatric nephrotic syndrome.
- Optimizing therapy requires careful consideration of individual patient factors and vigilant monitoring to minimize adverse events.
- Balancing efficacy with safety remains a key challenge in managing this condition.
Abstract:
Idiopathic childhood nephrotic syndrome generally has a favorable long-term prognosis. Prompt administration of and improved guidelines for monitoring therapy have decreased morbidity and mortality. The treatment goal is to induce prompt remission while minimizing complications and adverse events. Aggressive therapy induces remission and decreases the frequency of relapse in most patient populations; however, such treatment often results in unnecessary toxicity. We critically assessed the current clinical evidence that supports each pharmacologic therapy. For each drug regimen, the risks and monitoring parameters required to reduce complications and optimize therapy are discussed. Some of the treatments are the common corticosteroid approaches, cytotoxic therapies (chlorambucil, cyclophosphamide), cyclosporine, less frequently used drugs (e.g., levamisole), and experimental therapies. Further studies are needed to identify the most effective and least toxic therapeutic regimens for inducing and maintaining remission in children with nephrotic syndrome.